Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Li-Yaun Bai"'
Autor:
Hui-Jen Tsai, Yan-Shen Shan, Ching-Yao Yang, Chin-Fu Hsiao, Chung-Hsin Tsai, Chuan-Cheng Wang, Ming-Tsan Lin, Chun-Fu Ting, De-Chuan Chan, Te-Hung Chen, Chueh-Chuan Yen, Yen-Yang Chen, Hsuan-Yu Lin, Ta-Sen Yeh, Ching-Liang Ho, Tze-Yu Shieh, Li-Yaun Bai, Jun-Te Hsu, I-Shu Chen, Li-Tzong Chen, Chun-Nan Yeh, Taiwan Cooperative Oncology Group (TCOG) GIST Study Group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Most gastrointestinal stromal tumors (GISTs) harbor c-KIT or PDGFRA mutations. Administration of tyrosine kinase inhibitors (TKIs) has significantly improved the survival of patients with GISTs. We aimed to evaluate the clinical o
Externí odkaz:
https://doaj.org/article/7a0d574698304a8490d98afe0adaa589
Autor:
Ching-Yuan Kuo, Po-Nan Wang, Hwang, Wen-Li, Cheng-Hwai Tzeng, Li-Yaun Bai, Jih-Luh Tang, Ming-Chih Chang, Sheng-Fung Lin, Tsai-Yun Chen, Yeu-Chin Chen, Tran-Der Tan, Chih-Yi Hsieh, Chinjune Lin, Lai, Clinton, Miljkovic, Darko, Cheng-Shyong Chang
Supplemental material, Supplementary_Figure-1_submission_TAH for Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::602e972aae0ff4b63ee4214273cbf547
Autor:
Wen-Li Hwang, Li-Yaun Bai, Po-Nan Wang, Jih-Luh Tang, Chih-Yi Hsieh, Clinton Lai, Tsai Yun Chen, Tran-Der Tan, Sheng-Fung Lin, Ming-Chih Chang, Chinjune Lin, Ching-Yuan Kuo, Cheng-Hwai Tzeng, Cheng-Shyong Chang, Yeu-Chin Chen, Darko Miljkovic
Publikováno v:
Therapeutic advances in hematology. 9(3)
Background: Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), is approved for the treatment of patients with chronic myeloid leukemia (CML) in many countries, including Taiwan. Though a number of controlled clinical trials have demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::875c05cc48d5594e2afd4f679016ba3c
https://pubmed.ncbi.nlm.nih.gov/29531660
https://pubmed.ncbi.nlm.nih.gov/29531660
Autor:
Tseng Hsi Lin, Li Yaun Bai, Tung Huei Lin, Yii Jenq Lan, Chia Hui Chang, Pei Ching Hsiao, Tsai Yun Chen, Ching Yuan Kuo, Ming Chung Wang, Lee Yung Shih, Ming Chung Kuo, Chang Liang Lai, Tung Liang Lin, Youngsen Yang, Chih-Cheng Chen
Publikováno v:
Leukemia Research. 37:43-49
Some chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitor (TKI) do not respond or relapse. BCR-ABL1 mutations are the principal cause of TKI resistance, but the kinetics of emerging mutations in CML patients treated with ima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e838d7247faac756720e53c4ef684af4
https://doi.org/10.1016/j.leukres.2012.09.012
https://doi.org/10.1016/j.leukres.2012.09.012
Autor:
Pei-Ching Hsiao, Tseng-Hsi Lin, Su-Peng Yeh, Ching-Yuan Kuo, Tsai Yun Chen, Wen-Li Hwang, Yii-Jenq Lan, Lee-Yung Shih, Chih-Cheng Chen, Li-Yaun Bai, Ming-Chung Wang, Ming-Chung Kuo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 14:S138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::901205cfdf92457c7cf436d7132b7f45
https://doi.org/10.1016/j.clml.2014.06.070
https://doi.org/10.1016/j.clml.2014.06.070